Drug updated on 7/25/2024
| Dosage Form | Solution (topical; 0.015 mg/mL) |
| Drug Class | Prostaglandin analogs |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Latest News
Summary
- Tafluprost ophthalmic solution (Zioptan) is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
- The information was derived from two systematic reviews/meta-analyses studies.
- In a comparative study, Zioptan showed good IOP reduction but was numerically outperformed by latanoprostene bunod (LBN) and bimatoprost 0.03%.
- Another meta-analysis found that combining NSAIDs with prostaglandin analogs like tafluprost significantly improved IOP reduction compared to monotherapy.
- No specific safety data were mentioned for each drug; however, combination therapy typically requires monitoring for anti-inflammatory adverse effects.
- Overall, Zioptan is effective on its own and can have enhanced efficacy when combined with topical NSAIDs.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Zioptan (tafluprost) Prescribing Information. | 2022 | Théa Pharma Inc., Lexington, MA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| European Glaucoma Society terminology and guidelines for glaucoma, 4th edition - Chapter 3: Treatment principles and options supported by the egs foundation. | 2023 | British Journal of Ophthalmology |
| Effect of topical prostaglandin analogue therapy on central corneal thickness: A systematic review. | 2022 | Journal of Clinical Medicine |
| Primary open-angle glaucoma preferred practice pattern. | 2020 | American Academy of Ophthalmology |
| Clinical practice guide for the diagnosis and management of open angle glaucoma. | 2020 | Optometry Australia |